Ignite Creation Date:
2025-12-24 @ 10:55 PM
Ignite Modification Date:
2025-12-25 @ 8:23 PM
Study NCT ID:
NCT02745769
Status:
COMPLETED
Last Update Posted:
2019-03-05
First Post:
2016-04-18
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents
Sponsor:
Eli Lilly and Company
Organization:
Study Overview
Official Title:
An Open-Label, Phase 1a/1b Study of Ramucirumab in Combination With Other Targeted Agents in Advanced Cancers
Status:
COMPLETED
Status Verified Date:
2019-03-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of this study is to evaluate the safety of ramucirumab in combination with other targeted agents in participants with advanced cancers.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: